K.V. Turcheniuk, I.V. Shevchenko / Journal of Fluorine Chemistry 135 (2012) 379–382
381
4.1.1. 4,4,4-Trifluoro-3-(trifluoromethyl)-2-
4.2.2. (E)-2,2,4,4-Tetrakis(trifluoromethyl)-6-[3,3,3-trifluoro-2-
(trifluoromethyl)-1-(triisopropoxyphosphoranylidene)propyl]-4H-
1,3,5-dioxazine (4b)
[tris(dimethylamino)phosphoranylidene]-butanenitrile (3a)
White solid (148.5 mg, 84.3%), mp 184–186 8C. 1H NMR
(400 MHz, CDCl3):
d
2.7 (1H, m, CH(CF3)2), 2.7 (18H, d,
11.0 (1C, dm,
Colorless crystals (59.1 mg, 40.5%), mp 48–50 8C. 1H NMR
J = 9.3 Hz, CH3); 13C{1H} NMR (100 MHz, CDCl3):
d
(400 MHz, CDCl3):
J = 20.0 Hz, J = 9.3 Hz, CH(CF3)2), 4.9 (1H, oct, J = 6.4 Hz); 13C{1H}
NMR (100.6 MHz, CDCl3): 23.2 (6C, d, J = 5 Hz, CH3), 43.3 (1C, dm,
d 1.4 (18H, d, J = 6.4 Hz, CH3), 3.9 (1H, dsept,
J = 232 Hz, P55C), 37.3 (6C, d, J = 4 Hz, CH3), 46.4 (1C, dsept,
J = 30 Hz, J = 15 Hz, CH(CF3)2), 123.8 (2C, q, J = 284 Hz, CF3), 124.9
(1C, d, J = 14 Hz, CN); 19F NMR (84 MHz, CDCl3):
J = 9 Hz, CH(CF3)2); 31P{1H} NMR (36.2 MHz, CDCl3):
APCI-MS m/z: 353.1 [M+H]+.
d
d
d
67.4 (6F, d,
64.1 (1P, s);
J = 237 Hz, P55C), 48.2 (1C, dsept, J = 32 Hz, J = 11 Hz, CH(CF3)2),
76.1 (3C, d, J = 8 Hz, P–C), 83.4 (1C, m, C(CF3)2), 91.5 (1C, m,
C(CF3)2), 118.7 (2C, q, J = 290 Hz, CF3), 120.5 (2C, q, J = 290 Hz, CF3),
123.3 (2C, q, J = 282 Hz, CF3), 159.6 (1C, d, J = 18 Hz, C55N); 19F NMR
4.1.2. 4,4,4-Trifluoro-3-(trifluoromethyl)-2-
(84 MHz, CDCl3):
d
À83.2 (6F, br s, CF3), À82.5 (6F, br s, CF3), À67.4
(triisopropoxyphosphoranylidene)butanenitrile (3b)
(6F, br s, CH(CF3)2); 31P{1H} NMR (36.2 MHz, CDCl3): 41.2 (1P, s).
White needless (196.7 mg, 99%), mp 44–46 8C. 1H NMR
(400 MHz, CDCl3):
J = 15.6 Hz, J = 8.3 Hz, CH(CF3)2), 4.8 (1H, oct, J = 6.34 Hz); 13C{1H}
NMR (100.6 MHz, CDCl3): 9.2 (1C, dm, J = 270 Hz, P55C), 23.3 (6C,
d, J = 5 Hz, CH3), 46.5 (1C, dsept, J = 30 Hz, J = 11 Hz, CH(CF3)2), 75.5
(3C, d, J = 6 Hz, CH), 122.0 (1C, d, J = 18 Hz, CN), 123.5 (2C, q,
d
1.4 (18H, d, J = 6.3 Hz, CH3), 3.1 (1H, dsept,
4.2.3. (Z)-2,2,4,4-Tetrakis(trifluoromethyl)-6-[3,3,3-trifluoro-2-
(trifluoromethyl)-1-(triisopropoxyphosphoranylidene)propyl]-4H-
1,3,5-dioxazine (4b)
d
1H NMR (400 MHz, CDCl3):
d
1.4 (18H, d, J = 6.4 Hz, CH3), 4.4
(1H, dsept, J = 29.3 Hz, J = 9.3 Hz, CH(CF3)2), 4.8 (1H, oct, J = 6.4 Hz,
CH(CH3)2); 13C{1H} NMR (100.6 MHz, CDCl3):
23.0 (6C, d, J = 5 Hz,
J = 282 Hz, CF3); 19F NMR (84 MHz, CDCl3):
d
À67.8 (6F, d, J = 8 Hz,
46.7 (1P, s); ESI-MS
d
CH(CF3)2); 31P{1H} NMR (36.2 MHz, CDCl3):
d
CH3), 44.3 (1C, dm, J = 233 Hz, P55C), 46.8 (1C, dsept, J = 31 Hz,
J = 8 Hz, CH(CF3)2), 84.3 (1C, m, C(CF3)2), 90.9 (1C, m, C(CF3)2),
118.8 (2C, q, J = 290 Hz, CF3), 120.6 (2C, q, J = 290 Hz, CF3), 123.4
(2C, q, J = 282 Hz, CF3), 159.3 (1C, d, J = 18 Hz, C55N); 19F NMR
m/z: 398.2 [M+H]+.
4.1.3. 4,4,4-Trifluoro-2-(tributylphosphoranylidene)-3-
(trifluoromethyl)butanenitrile (3c)
(84 MHz, CDCl3):
d
À83.4 (6F, br s, CF3), À82.1 (6F, br s, CF3), À66.7
White needless (160.5 mg, 82%), mp 94–96 8C. 1H NMR
(6F, d, J = 9 Hz, CH(CF3)2); 31P{1H} NMR (36.2 MHz, CDCl3): 39.0
(400 MHz, CDCl3):
(CH2)2), 1.8–1.9 (6H, m, CH2), 2.9 (1H, dsept, J = 15.6 Hz, J = 6.2 Hz,
CH(CF3)2); 13C{1H} NMR (100.6 MHz, CDCl3):
0.3 (1C, dm,
J = 135 Hz, P55C), 13.2 (3C, s, CH3), 22.0 (3C, d, J = 55 Hz, P–C), 23.1
(3C, d, J = 3 Hz, CH2), 23.7 (3C, d, J = 15 Hz, CH2), 46.6 (1C, dsept,
J = 29 Hz, J = 11 Hz, CH(CF3)2), 123.6 (2C, q, J = 286 Hz, CF3), 125.0
d
0.9 (9H, t, J = 6.8 Hz, CH3), 1.4–1.6 (12H, m,
(1P, s).
d
4.2.4. (E)-2,2,4,4-Tetrakis(trifluoromethyl)-6-[3,3,3-trifluoro-1-
(tributylphosphoranylidene)-2-(trifluoromethyl)propyl]-4H-1,3,5-
dioxazine (4c)
Colorless crystals (67 mg, 46.3%), mp 84–86 8C. 1H NMR
(1C, d, J = 13 Hz, CN); 19F NMR (84 MHz, CDCl3):
d
À67.4 (6F, d,
d 30.5 (1P, s);
(400 MHz, CDCl3):
(CH2)2), 2.0–2.1 (6H, m, P–CH2), 2.86 (1H, dsept, J = 16.1 Hz,
J = 8.3 Hz, CH(CF3)2); 13C{1H} NMR (100.6 MHz, CDCl3):
13.1 (3C,
d 0.9 (9H, t, J = 6.8 Hz, CH3), 1.4–1.5 (12H, m,
J = 7 Hz, CH(CF3)2); 31P{1H} NMR (36.2 MHz, CDCl3):
APCI-MS m/z: 392.3 [M+H]+.
d
s, CH3), 19.7 (3C, d, J = 56 Hz, P–C), 23.3 (3C, d, J = 4 Hz, CH2), 23.6
(3C, d, J = 15 Hz, CH2), 34.0 (1C, d, J = 120 Hz, P55C), 47.9 (1C, dsept,
J = 31 Hz, J = 10 Hz, CH(CF3)2), 83.8 (1C, m, C(CF3)2), 91.1 (1C, m,
C(CF3)2), 118.9 (2C, q, J = 290 Hz, CF3), 120.2 (2C, q, J = 290 Hz, CF3),
123.2 (2C, q, J = 282 Hz, CF3), 158.1 (1C, d, J = 20 Hz, C55N); 19F NMR
4.2. Dioxazines 4a–c: common procedure
Hexafluoroacetone (2.5 equiv.) was condensed in a solution
of ylide (0.2 mmol) in CDCl3 (2 mL) in a small autoclave (10 mL).
The reaction mixture was heated at 50 8C for 2 h and then left at
room temperature for 4 days. As the reaction goes almost
quantitatively, CDCl3 was used as a solvent to record the NMR
spectra of the reaction solutions. In the case of R = NMe2 the
formation of only E-isomer was observed in the reaction
solution. Compounds 4a, 4c crystallized from the reaction
mixture in 3 days at À16 8C. Compound 4b crystallized from
hexane at À16 8C during 3 days. In all cases the solvent could
slowly evaporate from the crystallization flask through a needle
to provide the slow concentration of the solution during
crystallization. In crystalline form the compounds exist as E-
isomers.
(84 MHz, CDCl3):
d
À80.7 (6F, br s, CF3), À80.5 (6F, br s, CF3), À64.3
(6F, br d, J = 8 Hz, CH(CF3)2); 31P{1H} NMR (36.2 MHz, CDCl3):
d
28.9 (1P, s).
4.2.5. (Z)-2,2,4,4-Tetrakis(trifluoromethyl)-6-[3,3,3-trifluoro-1-
(tributylphosphoranylidene)-2-(trifluoromethyl)propyl]-4H-1,3,5-
dioxazine (4c)
1H NMR (400 MHz, CDCl3):
d
0.9 (9H, t, J = 7.2 Hz, CH3), 1.3–1.5
(12H, m, (CH2)2), 2.1–2.2 (6H, m, P–CH2), 4.6 (1H, dsept, J = 23.5 Hz,
J = 9.8 Hz, CH(CF3)2); 13C{1H} NMR (100.6 MHz, CDCl3):
13.3 (3C,
d
s, CH3), 19.5 (3C, d, J = 55 Hz, P–CH2), 23.5 (3C, d, J = 4 Hz, CH2), 23.9
(3C, d, J = 14 Hz, CH2), 36.2 (1C, d, J = 114 Hz, P55C), 46.4 (1C, dsept,
J = 31 Hz, J = 6 Hz, CH(CF3)2), 84.4 (1C, m, C(CF3)2), 90.4 (1C, m,
C(CF3)2), 118.9 (2C, q, J = 290 Hz, CF3), 120.2 (2C, q, J = 290 Hz, CF3),
123.2 (2C, q, J = 282 Hz, CF3), 157.8 (1C, d, J = 18 Hz, C55N); 19F NMR
4.2.1. (E)-2,2,4,4-Tetrakis(trifluoromethyl)-6-{3,3,3-trifluoro-2-
(trifluoromethyl)-1-[tris(dimethylamino)phosphoranylidene]-
propyl}-4H-1,3,5-dioxazine (4a)
(84 MHz, CDCl3):
d
À80.9 (6F, br s, CF3), À80.3 (6F, br s, CF3), À64.0
Yellow crystals (63.4 mg, 46.3%), mp 99–101 8C. 1H NMR
(6F, d, J = 10 Hz, CH(CF3)2); 31P{1H} NMR (36.2 MHz, CDCl3):
d 26.9
(400 MHz, CDCl3):
J = 20.5 Hz, J = 8.8 Hz, CH(CF3)2); 13C{1H} NMR (100 MHz, CDCl3):
37.2 (6 C, d, J = 5 Hz, CH3), 44.0 (1 C, d, J = 200 Hz, P55C), 48.2 (1C,
dsept, J = 31 Hz, J = 14 Hz, CH(CF3)2), 83.8 (1C, m, C(CF3)2), 90.7
(1C, m, C(CF3)2), 118.8 (2C, q, J = 290 Hz, CF3), 120.1 (2C, q,
J = 289 Hz, CF3), 123.8 (2C, q, J = 282 Hz, CF3), 157.8 (1C, d,
d
2.7 (18H, d, J = 9.3 Hz, CH3), 3.2 (1H, dsept,
(1P, s).
d
4.3. 4,4,4-Trifluoro-N-[2,2,2-trifluoro-1-hydroxy-1-
(trifluoromethyl)ethyl]-3-(trifluoromethyl)-2-
(triisopropoxyphosphoran-ylidene)butanamide (6b)
J = 25 Hz, C55N); 19F NMR (84 MHz, CDCl3):
d
À80.8 (6F, s, CF3),
To dioxazine 4b (E/Z = 2:1) (30 mg, 0.041 mmol) in CDCl3
(0.5 mL) water (0.3 mL) was added. The reaction was conducted at
25 8C in a NMR tube to monitor the hydrolysis. After completion of
À79.9 (6F, s, CF3), À63.9 (6F, br s, CH(CF3)2); 31P{1H} NMR
(36.2 MHz, CDCl3):
d 64.8 (1P, s).